SUNNYVALE, Calif., May 1, 2019 /PRNewswire/ -- Accuray Incorporated
(NASDAQ: ARAY) announced today that the company has signed an
agreement with Hong Kong Sanatorium & Hospital (HKSH) for the
acquisition of two Synchrony® motion tracking and
correction technology[1] upgrades, to be used with the hospital's
Radixact® Systems. Synchrony is a sophisticated
tool developed to make it easier to provide precise radiation
treatments to all tumors, even those that move. The agreement was
signed at the annual congress of the European Society for
Radiotherapy and Oncology (ESTRO) and represents the first
commercial sale of Synchrony for Radixact in Asia and the first achieved at ESTRO,
independent of the Synchrony product evaluation sites.
The Synchrony technology was originally developed to expand the
CyberKnife® System's unique automatic motion tracking
and correction capabilities, and enhance the precision of radiation
treatments delivered to tumors that move with respiration. Based on
positive outcomes from long-term clinical use, Accuray is now
bringing Synchrony to the Radixact System with functionality
designed to enable the delivery of highly accurate radiation dose
to tumors that move as a result of bodily processes, including
respiration and digestion, as well as patient movement.
"The Hong Kong Sanatorium & Hospital clinical team has
extensive experience using the Accuray radiation therapy delivery
systems, first with the TomoTherapy® System and then
with the next-generation Radixact platform and the CyberKnife
System. The unique capabilities of these systems enable our
clinical team to offer each cancer patient a personalized and
precise treatment approach that best suits their particular
disease," said Mr. Wyman Li, Manager
(Administration) of HKSH. "Since we began using the CyberKnife
System we have learned first-hand the benefits that automatic
motion tracking and correction capabilities can bring to patient
treatments. When we were told about the availability of the
Synchrony motion tracking and correction feature for the Radixact
System, it was an easy decision to add motion synchronization
technology to this system as well."
"HKSH is an internationally recognized hospital dedicated to
using advanced medical technology to provide their patients with
the best possible care. We are honored to have the opportunity to
expand our relationship with their team and to partner with them on
our shared vision – to enable cancer patients to live longer,
better lives," said Joshua H.
Levine, President & Chief Executive Officer of Accuray.
"Treating tumors that move can be challenging without the right
technology. HKSH will be the first hospital in Asia to use Synchrony with the Radixact
System, reinforcing the hospital's commitment to investing in
technology that enables their clinical team to successfully deliver
radiation treatments to all appropriate tumors, even those that
move."
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences, and patient outcomes. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products, including new product offerings
and improvements; the company's ability to develop new products or
improve existing products to meet customers' needs; the company's
limited long-term clinical data supporting the safety and efficacy
of its products, including product improvements, for certain users
and such other risks identified under the heading "Risk Factors" in
the company's quarterly report on Form 10-Q, filed with the
Securities and Exchange Commission (the "SEC") on February 8, 2019 and as updated periodically with
the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jayme Maniatis
MSLGROUP
+1 (781) 684-6610
accuray@mslgroup.com
[1] "Synchrony® Motion Tracking and Correction
Technology" is synonymous with the development name: "Motion
Tracking and Compensation Feature for the Radixact®
Treatment Delivery System"
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hong-kong-sanatorium--hospital-signs-agreement-at-estro-to-acquire-the-synchrony-motion-tracking-and-correction-technology-for-the-accuray-radixact-system-300841479.html
SOURCE Accuray Incorporated